Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 4
2014 2
2015 1
2019 1
2020 1
2021 1
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
The GIST of targeted therapy for malignant melanoma.
Bello DM, Dematteo RP, Ariyan CE. Bello DM, et al. Ann Surg Oncol. 2014 Jun;21(6):2059-67. doi: 10.1245/s10434-013-3373-z. Epub 2014 Feb 15. Ann Surg Oncol. 2014. PMID: 24531699 Free PMC article. Review.
The data presented centers on imatinib, vemurafenib, and most recently dabrafenib, targeting KIT and BRAF mutations and their outcomes in GIST and melanoma. ...
The data presented centers on imatinib, vemurafenib, and most recently dabrafenib, targeting KIT and BRAF mutations and their outcome …
Pharmaceutical approval update.
Goldenberg MM. Goldenberg MM. P T. 2013 Nov;38(11):705-7. P T. 2013. PMID: 24391391 Free PMC article.
Vortioxetine (Brintellix) for major depressive disorder; ustekinumab (stelara) for psoriatic arthritis; and dabrafenib mesylate (Tafinlar) for metastatic melanoma....
Vortioxetine (Brintellix) for major depressive disorder; ustekinumab (stelara) for psoriatic arthritis; and dabrafenib mesylate …
Update on International Medical Taxonomies of Biomarkers and Their Applications in Management of Thyroid Cancers.
Trovato M. Trovato M. Diagnostics (Basel). 2022 Mar 9;12(3):662. doi: 10.3390/diagnostics12030662. Diagnostics (Basel). 2022. PMID: 35328215 Free PMC article. Review.
Sorafenib-tosylate, Doxorubicin-hydrochloride, Vandetanib, Cabozantinib-s-malate, Dabrafenib-mesylate, Trametinib-dimethyl-sulfoxide, Lenvatinib-mesylate, Pralsetinib and Selpercatinib are validated for TC treatment. ...Noteworthy are BRAF and RET/PTC alterat …
Sorafenib-tosylate, Doxorubicin-hydrochloride, Vandetanib, Cabozantinib-s-malate, Dabrafenib-mesylate, Trametinib-dimethyl-sul …
Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation.
Bershas DA, Ouellet D, Mamaril-Fishman DB, Nebot N, Carson SW, Blackman SC, Morrison RA, Adams JL, Jurusik KE, Knecht DM, Gorycki PD, Richards-Peterson LE. Bershas DA, et al. Drug Metab Dispos. 2013 Dec;41(12):2215-24. doi: 10.1124/dmd.113.053785. Epub 2013 Oct 4. Drug Metab Dispos. 2013. PMID: 24097902 Clinical Trial.
Hydroxy-dabrafenib undergoes further oxidation to carboxy-dabrafenib, which subsequently converts to desmethyl-dabrafenib via a pH-dependent decarboxylation. The half-lives for carboxy- and desmethyl-dabrafenib were longer than for parent and hydroxy- …
Hydroxy-dabrafenib undergoes further oxidation to carboxy-dabrafenib, which subsequently converts to desmethyl-dabrafenib …
Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift.
Nussbaum PE, Nussbaum LA, Torok CM, Patel PD, Yesavage TA, Nussbaum ES. Nussbaum PE, et al. J Clin Pharm Ther. 2022 Jun;47(6):826-831. doi: 10.1111/jcpt.13600. Epub 2022 Jan 12. J Clin Pharm Ther. 2022. PMID: 35023192 Review.
CASE SUMMARY: A 35-year-old man underwent a craniotomy and subtotal resection of a large BRAF-V600E-positive papillary craniopharyngioma before referral to our institution. Our treatment included the BRAF-V600 inhibitor dabrafenib mesylate (75 mg, twice/day) and tra …
CASE SUMMARY: A 35-year-old man underwent a craniotomy and subtotal resection of a large BRAF-V600E-positive papillary craniopharyngioma bef …
[Melanoma: from molecular studies to the treatment breakthrough].
Imianitov EN. Imianitov EN. Arkh Patol. 2013 Sep-Oct;75(5):63-72. Arkh Patol. 2013. PMID: 24341237 Review. Russian.
Clinical trials involving specific BRAF inhibitors--vemurafenib and dabrafenib--demonstrated high efficacy of these agents towards BRAF-mutated melanoma. ...
Clinical trials involving specific BRAF inhibitors--vemurafenib and dabrafenib--demonstrated high efficacy of these agents towards BR …
Interaction of Anticancer Drugs with Human Organic Anion Transporter hOAT4.
Liu C, Zhang J, You G. Liu C, et al. J Oncol. 2019 Feb 28;2019:1951786. doi: 10.1155/2019/1951786. eCollection 2019. J Oncol. 2019. PMID: 30941173 Free PMC article.
The IC(50) values for epirubicin hydrochloride and dabrafenib mesylate were 5.240.95 muM and 8.303.30 muM, respectively. Dixon plot analysis revealed that inhibition by epirubicin hydrochloride was noncompetitive with a K(i) = 3 muM whereas inhibition by dabrafen …
The IC(50) values for epirubicin hydrochloride and dabrafenib mesylate were 5.240.95 muM and 8.303.30 muM, respectively. Dixon …
Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro evaluation of drug-drug interaction mediated by P-glycoprotein.
Lafaie L, Hodin S, Saïb S, Bin V, Bertoletti L, Delavenne X. Lafaie L, et al. Fundam Clin Pharmacol. 2022 Oct;36(5):860-868. doi: 10.1111/fcp.12769. Epub 2022 Feb 28. Fundam Clin Pharmacol. 2022. PMID: 35174529
IC(50) values of less than 10 muM were observed with the combination of erlotinib, nilotinib with both DOACs, and with dabrafenib and apixaban. IC(50) values between 10 and 100 muM were seen for axitinib, crizotinib, dasatinib, imatinib, and lapatinib with apixaban, and fo …
IC(50) values of less than 10 muM were observed with the combination of erlotinib, nilotinib with both DOACs, and with dabrafenib and …
Analyses of Ocular Adverse Reactions Associated With Anticancer Drugs Based on the Japanese Pharmacovigilance Database.
Tanaka J, Koseki T, Kondo M, Ito Y, Yamada S. Tanaka J, et al. Anticancer Res. 2022 Sep;42(9):4439-4451. doi: 10.21873/anticanres.15944. Anticancer Res. 2022. PMID: 36039456
RESULTS: Safety signals associated with anticancer drugs were detected for periorbital and eyelid disorders (imatinib), conjunctival disorders (imatinib and lapatinib), corneal disorders (S-1, erlotinib, capecitabine, cetuximab, gefitinib, vandetanib, trastuzumab emtansine, lapat …
RESULTS: Safety signals associated with anticancer drugs were detected for periorbital and eyelid disorders (imatinib), conjunctival disorde …
13 results